GlySure’s Technology May Break Barrier For Tight Control And Automated Glucose Monitoring
GlySure’s technology enables a healthcare facility to implement tight glycemic control and intensive insulin therapy.
GlySure’s technology enables a healthcare facility to implement tight glycemic control and intensive insulin therapy.
Biovista announced recently that it has entered into a research collaboration agreement with Novartis.
WaferGen Biosystems is a leader in the development, manufacture, and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries.
ADS Biotechnology has developed a breakthroughtechnology that upon administration immediately prevents any further blood vessel leakage, thereby effectively treating and reversing CLS.
In 2010, NCI estimated that 207,090 women were diagnosed with breast cancer, while 39,840 women likely died from the disease.
Infertility is one of the most impacting and daunting conditions in Women’s Health medicine, afflicting approximately 10% of the female population. To address this condition, […]
ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
An important drawback of current diabetes treatment regimens is patient compliance, particularly for insulin injections that are painful and must also be timely administered.
Nitric oxide is one of the most important physiological signaling molecules in the body, responsible for regulating such fundamental biological processes as proper blood vessel function and the body’s defense against infection.
Ikonisys is a medical devices company that has developed a combinatorial technological platform using molecular biology and imaging methodology for the detection of rare cells, […]
Copyright © 2024 | WordPress Theme by MH Themes